MA45491A - Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés - Google Patents

Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés

Info

Publication number
MA45491A
MA45491A MA045491A MA45491A MA45491A MA 45491 A MA45491 A MA 45491A MA 045491 A MA045491 A MA 045491A MA 45491 A MA45491 A MA 45491A MA 45491 A MA45491 A MA 45491A
Authority
MA
Morocco
Prior art keywords
cmh
binding molecules
related methods
restricted epitopes
epitopes
Prior art date
Application number
MA045491A
Other languages
English (en)
Inventor
Allen Ebens
Mark Frohlich
James Sissons
Semih U Tareen
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of MA45491A publication Critical patent/MA45491A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA045491A 2016-06-27 Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés MA45491A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662355236P 2016-06-27 2016-06-27

Publications (1)

Publication Number Publication Date
MA45491A true MA45491A (fr) 2019-05-01

Family

ID=59351076

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045491A MA45491A (fr) 2016-06-27 Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés

Country Status (8)

Country Link
US (1) US20190324030A1 (fr)
EP (2) EP3475706B1 (fr)
JP (2) JP7054397B2 (fr)
CN (1) CN109937364B (fr)
CA (1) CA3027999A1 (fr)
ES (1) ES2894257T3 (fr)
MA (1) MA45491A (fr)
WO (1) WO2018005556A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140525A1 (fr) * 2017-01-24 2018-08-02 Abexxa Biologics, Inc. Méthodes et compositions destinées à cibler un complexe comprenant un hla-i non classique et un néo-antigène dans le traitement du cancer
WO2019070541A1 (fr) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. Molécules de liaison spécifique à l'hpv
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
MX2020010460A (es) 2018-04-05 2021-01-29 Juno Therapeutics Inc Receptores de células t, y células diseñadas que expresan los mismos.
EP3827021A4 (fr) * 2018-07-23 2022-08-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anticorps ciblant un complexe comprenant hla-i non classique et néoantigène et leurs procédés d'utilisation
WO2020122104A1 (fr) * 2018-12-11 2020-06-18 国立大学法人京都大学 Procédé pour induire une délétion dans de l'adn génomique
CN109913414A (zh) * 2019-03-21 2019-06-21 吉林省银丰生物工程技术有限公司 肝癌afp特异性人工抗原递呈细胞诱导试剂盒
EP3946439A4 (fr) * 2019-03-30 2023-08-02 BioNTech US Inc. Compositions et procédés de préparation de compositions de lymphocytes t et leurs utilisations
TW202115245A (zh) 2019-06-27 2021-04-16 丹麥商諾佛 儂迪克股份有限公司 安全免疫隱形細胞
EP4004055A1 (fr) * 2019-07-26 2022-06-01 Janssen Biotech, Inc. Récepteur antigénique chimérique anti-hk2 (car)
CN110734474B (zh) * 2019-11-29 2021-10-19 中山大学 一种抗菌肽的筛选方法及其应用
CN111116716B (zh) * 2020-03-03 2022-03-01 中国医科大学 一种与骨髓瘤细胞高表达抗原hla-e特异性结合的多肽及其用途
US11976120B2 (en) 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981997B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981996B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
WO2022047325A1 (fr) * 2020-08-31 2022-03-03 The Trustees Of Columbia University In The City Of New York Ciblage de tmg4 pour le traitement du cancer de la prostate
AR124419A1 (es) 2020-12-18 2023-03-29 Novo Nordisk As Células seguras invisibles para el sistema inmunitario
WO2022136215A1 (fr) 2020-12-21 2022-06-30 Novo Nordisk A/S Cellules immuno-furtives sûres
WO2024036303A2 (fr) * 2022-08-11 2024-02-15 The Trustees Of The University Of Pennsylvania Lymphocytes t universels et compositions et leurs méthodes d'utilisation
CN117976074A (zh) * 2024-03-29 2024-05-03 北京悦康科创医药科技股份有限公司 Mhc分子和抗原表位亲和力确定方法、模型训练方法及装置

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983001A (en) 1972-05-10 1976-09-28 Ceskoslovenska Akademie Ved Isolation of biologically active compounds by affinity chromatography
US4213860A (en) 1976-06-30 1980-07-22 Board of Regents, State of Florida for and on behalf of the University of Florida Affinity chromatography and substrate useful therefor
GB1602432A (en) 1976-12-15 1981-11-11 Atomic Energy Authority Uk Affinity chromatography
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4175182A (en) 1978-07-03 1979-11-20 Research Corporation Separation of high-activity heparin by affinity chromatography on supported protamine
US4431546A (en) 1981-04-27 1984-02-14 The Public Health Laboratory Services Board Affinity chromatography using metal ions
DE3271828D1 (en) 1981-04-27 1986-07-31 Health Lab Service Board High pressure liquid affinity chromatography
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5821058A (en) 1984-01-16 1998-10-13 California Institute Of Technology Automated DNA sequencing technique
US5171534A (en) 1984-01-16 1992-12-15 California Institute Of Technology Automated DNA sequencing technique
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4811218A (en) 1986-06-02 1989-03-07 Applied Biosystems, Inc. Real time scanning electrophoresis apparatus for DNA sequencing
IN165717B (fr) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5149625A (en) 1987-08-11 1992-09-22 President And Fellows Of Harvard College Multiplex analysis of DNA
CA1340807C (fr) 1988-02-24 1999-11-02 Lawrence T. Malek Procede d'amplification d'une sequence d'acide nucleique
JP2650159B2 (ja) 1988-02-24 1997-09-03 アクゾ・ノベル・エヌ・ベー 核酸増幅方法
SE8801070D0 (sv) 1988-03-23 1988-03-23 Pharmacia Ab Method for immobilizing a dna sequence on a solid support
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US4962020A (en) 1988-07-12 1990-10-09 President And Fellows Of Harvard College DNA sequencing
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990002809A1 (fr) 1988-09-02 1990-03-22 Protein Engineering Corporation Production et selection de proteines de liaison diversifiees de recombinaison
US5075216A (en) 1988-09-23 1991-12-24 Cetus Corporation Methods for dna sequencing with thermus aquaticus dna polymerase
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5043062A (en) 1989-02-21 1991-08-27 Eastman Kodak Company High performance affinity chromatography column comprising non-porous, nondisperse polymeric packing material
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
KR0185192B1 (ko) 1989-10-05 1999-04-01 제임스 더블유. 데이비 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
DE69112207T2 (de) 1990-04-05 1996-03-28 Roberto Crea "walk-through"-mutagenese.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (fr) 1990-07-10 2002-10-01 Gregory P. Winter Methodes de production de membres de paires de liaison specifiques
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
EP0564531B1 (fr) 1990-12-03 1998-03-25 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE4123760C2 (de) 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
US20030036092A1 (en) 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
GB9208733D0 (en) 1992-04-22 1992-06-10 Medical Res Council Dna sequencing method
EP0656788B1 (fr) 1992-08-07 2006-10-18 Pharmexa Inc. Peptides de liaison de hla, et leurs utilisations
CA2153387A1 (fr) 1993-01-07 1994-07-21 Hubert Koester Sequencage de l'adn par spectrometrie de masse
US5374527A (en) 1993-01-21 1994-12-20 Applied Biosystems, Inc. High resolution DNA sequencing method using low viscosity medium
US5989565A (en) 1993-01-29 1999-11-23 University Of Pittsburgh Elution and identification of T cell epitopes from viable cells
CA2155186A1 (fr) 1993-02-01 1994-08-18 Kevin M. Ulmer Methodes et appareil pour le sequencage de l'adn
KR960700739A (ko) 1993-03-05 1996-02-24 카린 이스텀 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)
CA2158642A1 (fr) 1993-03-19 1994-09-29 Hubert Koster Sequencage de l'adn par spectrometrie de masse, via la degradation de l'exonuclease
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5654419A (en) 1994-02-01 1997-08-05 The Regents Of The University Of California Fluorescent labels and their use in separations
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (fr) 1994-10-26 1996-05-09 Procept, Inc. Recepteurs de lymphocites t monocatenaires solubles
WO1996018105A1 (fr) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Recepteur de lymphocyte t monocatenaire
US5840306A (en) 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
DK0862656T3 (da) 1995-11-21 2001-04-09 Univ Yale Unimolekylær segmentamplifikation og -detektering
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
WO1997032603A1 (fr) 1996-03-05 1997-09-12 The Scripps Research Institute Elements recombinants codant pour des recepteurs de lymphocytes t specifiques des antigenes de tumeurs limites par hla humains
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (fr) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple
US5846727A (en) 1996-06-06 1998-12-08 Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College Microsystem for rapid DNA sequencing
GB9618050D0 (en) 1996-08-29 1996-10-09 Cancer Res Campaign Tech Global amplification of nucleic acids
EP0962527B1 (fr) 1996-10-17 2004-08-04 Mitsubishi Chemical Corporation Molecule permettant d'homologuer un genotype et un phenotype, et utilisation de celle-ci
US5858671A (en) 1996-11-01 1999-01-12 The University Of Iowa Research Foundation Iterative and regenerative DNA sequencing method
US6258533B1 (en) 1996-11-01 2001-07-10 The University Of Iowa Research Foundation Iterative and regenerative DNA sequencing method
US5876934A (en) 1996-12-18 1999-03-02 Pharmacia Biotech Inc. DNA sequencing method
EP1712623B1 (fr) 1997-01-21 2011-10-19 The General Hospital Corporation Sélection de protéines par fusions de proteénes et d'ARN
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
CA2305630C (fr) 1997-10-02 2012-11-06 Sunol Molecular Corporation Proteines solubles du recepteur des lymphocytes t a chaine unique
TR200003391T2 (tr) 1998-05-19 2001-02-21 Avidex Limited Çözünür T hücresi reseptörü
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
IL143238A0 (en) 1998-12-02 2002-04-21 Phylos Inc Dna-protein fusions and uses thereof
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6385581B1 (en) 1999-05-05 2002-05-07 Stanley W. Stephenson System and method of providing emotive background sound to text
PT1054018E (pt) 1999-05-18 2009-02-16 Dyax Corp Bibliotecas de fragmentos fab e métodos para a sua utilização
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US6132997A (en) 1999-05-28 2000-10-17 Agilent Technologies Method for linear mRNA amplification
PT1870417E (pt) 1999-07-27 2012-06-01 Bristol Myers Squibb Co Métodos de ligação de aceitador peptídico
CA2388045C (fr) * 1999-10-20 2014-02-11 Tzyy-Choou Wu Compositions immunogeniques a base d'acide nucleique codant la chimere antigene hsp
US20060035338A1 (en) * 1999-12-17 2006-02-16 Pure Protein Llc Method and apparatus for the production of soluble MHC antigens and uses thereof
AU3095801A (en) * 2000-01-31 2001-08-07 Human Genome Sciences Inc Nucleic acids, proteins, and antibodies
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2410510A1 (fr) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
EP1377609B1 (fr) 2001-03-14 2015-06-24 Dako Denmark A/S Nouvelles constructions de molecules mhc, methodes d'utilisation de ces constructions a des fins de diagnostic et de therapie et utilisations de molecules mhc
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
PL208712B1 (pl) 2001-08-31 2011-05-31 Avidex Ltd Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (fr) 2002-02-20 2003-08-28 Dyax Corp. Ligands de liaison au complexe mhc-peptide
AU2003214076A1 (en) 2002-02-28 2003-09-09 Intercell Ag Method for isolating ligands eg T cell epitopes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
EP1773383B1 (fr) 2004-05-27 2012-09-12 Jon A. Weidanz Anticorps mimetiques de recepteurs de cellules t et leurs procedes de production et d'utilisation
EP3363907A1 (fr) 2004-05-27 2018-08-22 The Trustees of the University of Pennsylvania Nouvel antigène artificiel présentant des cellules et utilisations associées
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
JP5563194B2 (ja) 2004-06-29 2014-07-30 イムノコア リミテッド 改変ｔ細胞レセプターを発現する細胞
CA2582963A1 (fr) 2004-10-01 2006-04-13 Avidex Ltd Recepteurs de lymphocytes t a liaison intercatenaire disulfure exogene reliee a des agents therapeutiques
DE602004019215D1 (de) 2004-10-02 2009-03-12 Immatics Biotechnologies Gmbh Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden
GB0507598D0 (en) * 2005-04-14 2005-05-18 Trojantec Technologies Ltd Composition
WO2006116681A2 (fr) * 2005-04-28 2006-11-02 Caprion Pharmaceuticals, Inc. Tat-003 et procedes de determination et de traitement du cancer
JP5079697B2 (ja) 2005-08-05 2012-11-21 ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハー 抗原特異的ｔ細胞の生成方法
CN101431989B (zh) 2005-12-30 2011-11-23 雷文斯治疗公司 局部给药的精氨酸杂聚体
CN101490078A (zh) 2006-04-05 2009-07-22 通用医院有限公司 可溶性病毒特异性t细胞受体组合物
JP2010519256A (ja) * 2007-02-23 2010-06-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 免疫疾患を治療するために、ＨＬＡ−Ｅ／Ｑａ−１拘束性ＣＤ８＋Ｔ細胞制御性経路を活性化または遮断する方法
WO2008120203A2 (fr) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Procédés de diagnostic et de traitement de maladies provoquées par le cytomégalovirus
WO2008121420A1 (fr) 2007-03-30 2008-10-09 Memorial Sloan-Kettering Cancer Center Expression constitutive de ligands costimulants sur des lymphocytes t transférés de manière adoptive
ES2640216T3 (es) 2007-12-07 2017-11-02 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
NO2119726T3 (fr) * 2008-05-14 2015-05-23
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP3629022A1 (fr) 2008-07-25 2020-04-01 Richard W. Wagner Procédés de criblage de protéines
ES2961498T3 (es) 2008-08-26 2024-03-12 Hope City Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T
WO2010054010A1 (fr) 2008-11-07 2010-05-14 Fabrus Llc Anticorps anti-dll4 et utilisations associées
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
EP2483301A1 (fr) 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Récepteurs d'antigènes chimériques anti-récepteur 2 du facteur de croissance de l'endothélium vasculaire, et leur utilisation pour le traitement du cancer
CA2777053A1 (fr) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Recepteurs de lymphocytes t a chaine unique humains
SG177025A1 (en) 2010-06-21 2012-01-30 Agency Science Tech & Res Hepatitis b virus specific antibody and uses thereof
CA2798988C (fr) 2010-05-17 2020-03-10 Sangamo Biosciences, Inc. Polypeptides liant l'adn des tale et leurs utilisations
LT2618835T (lt) 2010-09-20 2017-10-10 Biontech Cell & Gene Therapies Gmbh Antigenui specifiniai t ląstelių receptoriai ir t ląstelių epitopai
BR122021026169B1 (pt) 2010-12-09 2023-12-12 The Trustees Of The University Of Pennsylvania Uso de uma célula
ES2926988T3 (es) 2011-03-15 2022-10-31 X Body Inc Métodos de cribado de anticuerpos
ES2841983T3 (es) 2011-03-23 2021-07-12 Hutchinson Fred Cancer Res Método y composiciones para inmunoterapia celular
KR20140033029A (ko) 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
KR102028340B1 (ko) 2011-04-13 2019-10-04 이뮤니쿰 에이비 항원-특이적 t 세포의 증식 방법
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
EP3766896A1 (fr) 2011-09-15 2021-01-20 The United States of America, as represented by The Secretary, Department of Health and Human Services Récepteurs des lymphocytes t reconnaissant un gène mage restreint par hla-a1 ou hla-cw7
CN102399265B (zh) * 2011-10-28 2014-06-25 中国人民解放军第四军医大学 Htnv-np 特异性的ctl 表位肽及其应用
BR112014011417B1 (pt) 2011-11-11 2021-10-13 Fred Hutchinson Cancer Research Center Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1
US20130156808A1 (en) * 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
EP2814846B1 (fr) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
KR20150009556A (ko) 2012-05-03 2015-01-26 프레드 헛친슨 켄서 리서치 센터 증강된 친화성 t　세포 수용체 및 이의 제조 방법
US10656156B2 (en) * 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
WO2014009348A1 (fr) 2012-07-10 2014-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour déterminer si une infection par un cytomégalovirus chez un patient greffé est susceptible d'induire un rejet d'allogreffe
MX2015000979A (es) 2012-07-27 2015-11-23 Univ Illinois Ingenieria de receptores de celulas t.
WO2014031687A1 (fr) 2012-08-20 2014-02-27 Jensen, Michael Procédé et compositions pour l'immunothérapie cellulaire
CN112430580A (zh) 2012-10-02 2021-03-02 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
RU2019137208A (ru) 2013-02-20 2020-02-19 Новартис Аг ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII
ES2696703T3 (es) 2013-03-05 2019-01-17 Univ Oregon Health & Science Vectores de citomegalovirus que permiten el control del direccionamiento de los linfocitos T
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
CN103421118B (zh) * 2013-07-16 2015-03-25 中国人民解放军第四军医大学 HTNV-Gn/Gc特异性CTL表位肽及其聚合物和应用
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
SG10201804335QA (en) 2013-11-22 2018-06-28 Univ Illinois Engineered high-affinity human t cell receptors
CN104163862B (zh) * 2013-12-04 2017-02-08 魏敏杰 与人mhc‑i类分子结合的grp78多肽表位
CN103933560B (zh) * 2013-12-09 2017-04-12 安徽农业大学 一种应用Ii‑Key活性四肽携带法氏囊VP2和新城疫HN抗原肽表位嵌合疫苗的制备方法
EP3099708B1 (fr) 2014-01-29 2019-09-04 University Health Network Procédés et compositions permettant la production d'une cellule exprimant un récepteur de l'antigène des lymphocytes t
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
RU2745319C2 (ru) 2016-03-16 2021-03-23 Нексиммьюн, Инк. Получение антигенспецифических t-клеток
AU2018361991A1 (en) * 2017-10-31 2020-05-14 Galectin Sciences, Llc Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
USD956212S1 (en) 2020-10-02 2022-06-28 Phillips-Medisize A/S Autoinjector

Also Published As

Publication number Publication date
CN109937364A (zh) 2019-06-25
US20190324030A1 (en) 2019-10-24
EP3475706A1 (fr) 2019-05-01
CN109937364B (zh) 2022-12-02
ES2894257T3 (es) 2022-02-14
JP2022081490A (ja) 2022-05-31
CA3027999A1 (fr) 2018-01-04
EP3475706B1 (fr) 2021-08-11
JP2019520591A (ja) 2019-07-18
WO2018005556A1 (fr) 2018-01-04
EP3992632A1 (fr) 2022-05-04
JP7054397B2 (ja) 2022-04-13
JP7340638B2 (ja) 2023-09-07

Similar Documents

Publication Publication Date Title
MA45491A (fr) Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
MA52273A (fr) Protéines de liaison à un antigène anti-trem2 et leurs utilisations
IL275510A (en) Specific antigen-binding molecules-ROR1
FR23C1012I1 (fr) Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
DK3370768T3 (da) Antistoffer som specifikt binder pd-1 og anvendelser deraf
DK3265575T3 (da) Cd20-bindende molekyler og anvendelser deraf
DK3347379T3 (da) Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA42059A (fr) Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
MA44060A (fr) Protéines de liaison à un antigène bispécifiques anti-tl1a/anti-tnf-alpha et leurs utilisations
MA42808A (fr) Anticorps de liaison à l'il-8 et leurs utilisations
DK3350220T3 (da) Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
DK3221356T3 (da) T-celleaktiverende, bispecifikke, antigenbindende molekyler mod folr1 og cd3
DK3328888T3 (da) ANTI-PSMA-antistoffer, bispecifikke antigenbindingsmolekyler, der binder PSMA AND og CD3, samt anvendelser deraf
MA45426A (fr) Procédés, kits, agents et appareils de transduction
MA42821A (fr) Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
IL256853A (en) antibody molecules that bind cd79
DK3116909T3 (da) Antistofmolekyler til lag-3 og anvendelser deraf
GB201605343D0 (en) Validation of the integrity of data
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
DK3645571T3 (da) Her3-antigen-bindende molekyler
DK3362477T3 (da) Antigenbindingsproteiner, der aktiverer leptinreceptoren
CY1125793T1 (el) Εξουδετερωτικα μορια δεσμευσης κατα της γριπης και χρησεις αυτων
DK3265123T3 (da) Antistoffer, anvendelser og fremgangsmåder